Search results
Results from the WOW.Com Content Network
A well studied model is celiac disease, in which increased intestinal permeability appears secondary to the abnormal immune reaction induced by gluten and allows fragments of gliadin protein to get past the intestinal epithelium, triggering an immune response at the intestinal submucosa level that leads to diverse gastrointestinal or extra ...
Class III – low permeability, high solubility . Example: cimetidine; The absorption is limited by the permeation rate but the drug is solvated very fast. If the formulation does not change the permeability or gastro-intestinal duration time, then class I criteria can be applied. Class IV – low permeability, low solubility . Example: bifonazole
Inflammatory cytokines (TNF-alpha, IL-6 and IL-8) are thought to be essential in the initiation and perpetuation of liver injury and cytotoxic hepatomegaly by inducing apoptosis and severe hepatotoxicity. One possible mechanism for the increased activity of TNF-α is the increased intestinal permeability due to liver disease.
Leaky gut syndrome is a hypothetical and medically unrecognized condition [1] [2] that is distinct from the scientific phenomenon of increased intestinal permeability commonly known as "leaky gut". [ 1 ] [ 3 ] Claims for the existence of "leaky gut syndrome" as a distinct medical condition come mostly from nutritionists and practitioners of ...
A prokinetic agent (also prokineticin, gastroprokinetic agent, gastrokinetic agent or propulsive) is a type of drug which enhances gastrointestinal motility by increasing the frequency or strength of contractions, but without disrupting their rhythm. [1]
The symptoms of bacterial overgrowth include nausea, flatus, [5] constipation, [6] bloating, abdominal distension, abdominal pain or discomfort, diarrhea, [7] fatigue, and weakness. SIBO also causes an increased permeability of the small intestine. [8] Some patients may lose weight.
Altered intestinal barrier function may play a role in the development of celiac disease. By allowing gliadin, the causative agent of celiac disease, to cross the intestinal barrier, inappropriate activation of the immune system can occur. Celiac disease sufferers have been shown to have elevated intestinal permeability and altered tight junctions.
First-pass metabolism may occur in the liver (for propranolol, lidocaine, clomethiazole, and nitroglycerin) or in the gut (for benzylpenicillin and insulin). [4] The four primary systems that affect the first pass effect of a drug are the enzymes of the gastrointestinal lumen, [5] gastrointestinal wall enzymes, [6] [7] [8] bacterial enzymes [5] and hepatic enzymes.